<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 31 Mar 2021 07:22:35 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>来吧！少年，我看你骨骼清奇，这里适合你</title><link>https://mp.weixin.qq.com/s/vSOYCJBfPtUyrhK_vRUSVg</link><description></description><content:encoded><![CDATA[来吧！少年，我看你骨骼清奇，这里适合你]]></content:encoded><pubDate>Tue, 30 Mar 2021 22:20:57 +0800</pubDate></item><item><title>看漫画 涨知识 I 都说男人善变，原来这是真的</title><link>https://mp.weixin.qq.com/s/MnKNVxQokPNCbJjAvmBIyA</link><description></description><content:encoded><![CDATA[看漫画 涨知识 I 都说男人善变，原来这是真的]]></content:encoded><pubDate>Tue, 30 Mar 2021 22:20:57 +0800</pubDate></item><item><title>看新闻 涨知识 I 奥希替尼即将在华获批NSCLC术后辅助适应症</title><link>https://mp.weixin.qq.com/s/s__rTvuFDf36s6xszpy9Uw</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I 奥希替尼即将在华获批NSCLC术后辅助适应症]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:27:19 +0800</pubDate></item><item><title>医学人想要加薪，先有“钱力”</title><link>https://mp.weixin.qq.com/s/cLF2daAtAFuC0YRsVcR00A</link><description></description><content:encoded><![CDATA[医学人想要加薪，先有“钱力”]]></content:encoded><pubDate>Tue, 30 Mar 2021 17:27:19 +0800</pubDate></item><item><title>一家药企用花园诠释其独特价值观</title><link>https://mp.weixin.qq.com/s/phYl6HczHDSFFHfgDD4N1A</link><description></description><content:encoded><![CDATA[一家药企用花园诠释其独特价值观]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:02:22 +0800</pubDate></item><item><title>刘艳艳教授点评 | 难治性外周T细胞淋巴瘤一例</title><link>https://mp.weixin.qq.com/s/_ghC5Fzkep2gHqSz3PPY1Q</link><description></description><content:encoded><![CDATA[刘艳艳教授点评 | 难治性外周T细胞淋巴瘤一例]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:02:22 +0800</pubDate></item><item><title>EGFR抑制剂Lazertinib中文版说明书</title><link>https://mp.weixin.qq.com/s/ftiU23w7ArCKDL2uMcAe7w</link><description></description><content:encoded><![CDATA[EGFR抑制剂Lazertinib中文版说明书]]></content:encoded><pubDate>Mon, 29 Mar 2021 19:02:22 +0800</pubDate></item><item><title>看新闻 涨知识 I 武田登革热疫苗获得EMA受理</title><link>https://mp.weixin.qq.com/s/Ol_CxTxDCAZqVYUuHIElfA</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I 武田登革热疫苗获得EMA受理]]></content:encoded><pubDate>Sun, 28 Mar 2021 15:42:48 +0800</pubDate></item><item><title>【ELCC 2021】周彩存教授报告Camel-sq研究结果，晚期鳞状NSCLC再迎一线治疗新选择</title><link>https://mp.weixin.qq.com/s/Eh3ZZpz_V58s0MySJbu-Sw</link><description></description><content:encoded><![CDATA[【ELCC 2021】周彩存教授报告Camel-sq研究结果，晚期鳞状NSCLC再迎一线治疗新选择]]></content:encoded><pubDate>Sun, 28 Mar 2021 15:42:48 +0800</pubDate></item><item><title>【2021EBMT】纳武利尤单抗(40mg)在R/R cHL的疗效研究</title><link>https://mp.weixin.qq.com/s/TAEdgWb0FpE5-3sSNO7qiA</link><description></description><content:encoded><![CDATA[【2021EBMT】纳武利尤单抗(40mg)在R/R cHL的疗效研究]]></content:encoded><pubDate>Sun, 28 Mar 2021 15:42:48 +0800</pubDate></item><item><title>武田罕见病药物 I 艾替班特在华即将获批</title><link>https://mp.weixin.qq.com/s/JiDiDa0SrrWRVIiZd04kHA</link><description></description><content:encoded><![CDATA[武田罕见病药物 I 艾替班特在华即将获批]]></content:encoded><pubDate>Sat, 27 Mar 2021 12:07:35 +0800</pubDate></item><item><title>【SGO 2021】纽约妇科肿瘤患者感染新冠后结局更差</title><link>https://mp.weixin.qq.com/s/Q4hmla-TfQICOhbaUqztlA</link><description></description><content:encoded><![CDATA[【SGO 2021】纽约妇科肿瘤患者感染新冠后结局更差]]></content:encoded><pubDate>Sat, 27 Mar 2021 12:07:35 +0800</pubDate></item><item><title>最燃现场，看武田年会玩出百变“新”意！</title><link>https://mp.weixin.qq.com/s/kOKHk7UCvtjaZtloqCkk7g</link><description></description><content:encoded><![CDATA[最燃现场，看武田年会玩出百变“新”意！]]></content:encoded><pubDate>Fri, 26 Mar 2021 21:23:13 +0800</pubDate></item><item><title>基石药业 I 首个RET抑制剂普拉替尼在华获批晚期NSCLC适应症</title><link>https://mp.weixin.qq.com/s/Fgo45KlSFvEOCQ9SFeapRw</link><description></description><content:encoded><![CDATA[基石药业 I 首个RET抑制剂普拉替尼在华获批晚期NSCLC适应症]]></content:encoded><pubDate>Thu, 25 Mar 2021 12:45:00 +0800</pubDate></item><item><title>看报告 涨知识 I 毕马威对中国十四五规划的分析</title><link>https://mp.weixin.qq.com/s/vVZbJPuXJDbcUMgUTVfJeQ</link><description></description><content:encoded><![CDATA[看报告 涨知识 I 毕马威对中国十四五规划的分析]]></content:encoded><pubDate>Thu, 25 Mar 2021 12:45:00 +0800</pubDate></item><item><title>【2021EBMT】MF患者接受芦可替尼治疗后进行alloHCT的疗效可观</title><link>https://mp.weixin.qq.com/s/etHSEoBcGibZ2cmtKgTApg</link><description></description><content:encoded><![CDATA[【2021EBMT】MF患者接受芦可替尼治疗后进行alloHCT的疗效可观]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:02:21 +0800</pubDate></item><item><title>MM课堂 | 李昕教授：高危多发性骨髓瘤的诊断与治疗</title><link>https://mp.weixin.qq.com/s/TbC8kUCGvCuVM9WnaxvOLA</link><description></description><content:encoded><![CDATA[MM课堂 | 李昕教授：高危多发性骨髓瘤的诊断与治疗]]></content:encoded><pubDate>Wed, 24 Mar 2021 21:02:21 +0800</pubDate></item><item><title>武田 I 加大中国投资 打造可持续医疗生态系统</title><link>https://mp.weixin.qq.com/s/u7jKvKKEeT9qQQ9k2BfOqw</link><description></description><content:encoded><![CDATA[武田 I 加大中国投资 打造可持续医疗生态系统]]></content:encoded><pubDate>Tue, 23 Mar 2021 23:16:23 +0800</pubDate></item><item><title>速递|IMpower010研究达到DFS主要终点，免疫治疗在早期NSCLC辅助治疗领域取得重大突破</title><link>https://mp.weixin.qq.com/s/FsfDzpbPzHIKCjIX7kPBZQ</link><description></description><content:encoded><![CDATA[速递|IMpower010研究达到DFS主要终点，免疫治疗在早期NSCLC辅助治疗领域取得重大突破]]></content:encoded><pubDate>Tue, 23 Mar 2021 23:16:23 +0800</pubDate></item><item><title>看新闻 涨知识 I 扬子江药业获得韩国大熊制药新型质子泵抑制剂独家权益</title><link>https://mp.weixin.qq.com/s/qCYR8idI1cH1j07r09gtbA</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I 扬子江药业获得韩国大熊制药新型质子泵抑制剂独家权益]]></content:encoded><pubDate>Mon, 22 Mar 2021 18:02:13 +0800</pubDate></item></channel></rss>